Altimmune Inc (NASDAQ: ALT), a clinical stage biotechnology Company developing immunotherapies for unmet medical needs, announced that the Company has completed designing and synthesis of a novel single-dose, intranasal vaccine to protect against COVID-19, developed using its proprietary intranasal vaccine technology. [caption id="attachment_20787" align="aligncenter" width="271"] Image...
Zelira Therapeutics (OTCQB: ZLDAF), a biopharmaceutical Company developing cannabinoid-based formulations for the treatment of a wide range of medical conditions, announced full enrollment in its Phase 1 Dose Escalation Trial in patients on long-term opioid treatment for non-cancer pain. The study intends to evaluate the...
Fabry Disease also known as angiokeratoma corporis diffusum or alpha-galactosidase A deficiency, is an inherited disorder characterized by the buildup of globotriaosylceramide, a type of fat in the body’s cells and results in numerous disorders such as acroparesthesias (burning, tingling, or prickling sensation in extremities),...
Alphatec Holdings (NASDAQ: ATEC), a medical technology company developing novel surgical products for treatment of spine disorders, announced the signing of an agreement to acquire EOS imaging, SA (EPA: EOSI), a leader in orthopedic medical imaging and software solutions, in a deal involving cash and...
Veru Inc (NASDAQ: VERU), an oncology and urology focused biopharmaceutical Company developing novel therapeutics for the treatment of prostate cancer, announced the initiation of a pivotal Phase 2 clinical trial of VERU-111, a first-in-class, oral, selective antitubulin agent, intended for the treatment of metastatic castration...
Baudax Bio (NASDAQ: BXRX), a pharmaceutical Company developing novel therapeutics for Acute Care Settings, announed the approval of a New Drug Application ( NDA) for ANJESO (meloxicam injection), intended for alleviating moderate to severe pain, either as a standalone treatment or in combination with other...
Kannalife Inc (OTCQB: KLFE), a biopharmaceutical Company developing CBD-based therapeutics for the treatment of neurodegenerative and neuropathic pain disorders, announced the grant of a patent Chinese Patent CN106456573B specific to "Novel Functionalized 1,3-Benzene Diols and their Method of Use for the Treatment of Hepatic Encephalopathy",...
Collegium Pharmaceutical (NASDAQ: COLL), a Speciality Pharmaceutical Company focussed on developing novel abuse-deterrent therapeutics for pain relief and management, announced the closing of its acquisition of the Nucynta franchise from Assertio Therapeutics (NASDAQ: ASRT), in consideration for $375.0 million in cash at closing, less royalties...
Abeona Therapeutics (NASDAQ: ABEO), a clinical-stage biopharmaceutical Company pioneering cell and gene-based therapies for rare genetic disease, announced positive interim data from two ongoing phase I/II clinical trials evaluating ABO-102 and ABO-101, indicated for the treatment of MPS IIIA and MPS IIIB. The study being...
The Global legal marijuana market is likely to reach over USD 66.3 billion by the end of 2025, as per a report by Grand View Research, Inc, growing at a CAGR of 23.9%. There is a growing acceptance of the curative effects of cannabis, with...
